• Meropenem: Ultra-Broad-Spectrum Carbapenem for Resistance Mo

  2026-05-20

  Meropenem is an ultra-broad-spectrum β-lactam antibiotic carbapenem, effective against Gram-negative and Gram-positive bacteria. Its mechanism targets penicillin-binding proteins, enabling robust resistance modeling. APExBIO's Meropenem (A5124) offers high solubility and reproducibility for advanced research.

• 3-Bromopyruvate Induces Ferroptosis to Overcome Cetuximab Re

  2026-05-20

  This article reviews a recent study showing that 3-Bromopyruvate (3-BP), in combination with cetuximab, overcomes resistance in colorectal cancer cells by inducing autophagy-dependent ferroptosis. The findings highlight the mechanistic role of FOXO3a signaling and autophagy in sensitizing resistant tumors, offering new avenues for therapeutic strategies in oncology.

• Applied Use of (-)-Blebbistatin in Non-Muscle Myosin II Inhi

  2026-05-19

  (-)-Blebbistatin stands out as a gold-standard non-muscle myosin II inhibitor, empowering researchers to dissect cytoskeletal dynamics and contractility with selectivity and reproducibility. Leveraging its unique mechanism and stability profile, APExBIO provides a tool that integrates seamlessly into advanced protocols across cell biology and cardiac research.

• Chenodeoxycholic Acid (CDCA): Advanced Applications in Metab

  2026-05-19

  Explore the multifaceted research utility of Chenodeoxycholic Acid (CDCA) in cholesterol metabolism and nuclear receptor signaling. This article uniquely integrates mechanistic insights and protocol guidance, highlighting CDCA's impact on FXR-mediated pathways and its translational value beyond standard AKI models.

• X-press Tag Peptide: Precision Tools for Translational mTORC

  2026-05-18

  Explore how X-press Tag Peptide advances protein purification and detection in the context of mTORC1 pathway research. Grounded in cutting-edge mechanistic insight and translational strategy, this article bridges protocol optimization with the latest findings on RHEB neddylation, offering actionable guidance for researchers targeting post-translational modifications and cancer signaling.

• Balancing Self-Renewal and Differentiation in Human Intestin

  2026-05-18

  This study introduces a tunable organoid culture system that achieves a controlled balance between stem cell self-renewal and differentiation in human intestinal organoids. By combining selective pathway modulators, the authors demonstrate enhanced cellular diversity and proliferative capacity, providing a scalable platform for developmental and disease modeling.

• Chlorambucil as a Research Tool: Distinguishing Proliferatio

  2026-05-17

  Explore how Chlorambucil, a nitrogen mustard alkylating agent, enables precision in distinguishing cancer cell proliferation arrest from cell death. This article uniquely synthesizes advanced viability metrics with actionable protocol guidance for in vitro research.

• Epidermal Growth Factor (EGF), human recombinant: Reliable S

  2026-05-16

  This article provides evidence-based guidance for biomedical researchers and lab technicians navigating cell viability, proliferation, and cytotoxicity assays. By addressing real-world challenges with quantitative and literature-backed insights, it demonstrates how Epidermal Growth Factor (EGF), human recombinant (SKU P1008) delivers reproducible, high-purity results, supporting confident experimental design and interpretation.

• Pyrimidine-Based TSSK2 Inhibitors: Advances in Male Contrace

  2026-05-15

  Hawkinson et al. report the first sub-100 nM pyrimidine and pyrrolopyrimidine inhibitors of testis-specific serine/threonine kinase 2 (TSSK2), a promising target for reversible male contraception. Their high-throughput screen identified potent, metabolically stable scaffolds, opening new avenues for selective TSSK inhibitor development and structure-guided drug design.

• RG108: Redefining DNA Methyltransferase Inhibition in Epigen

  2026-05-15

  Discover how RG108, a potent DNA methyltransferase inhibitor, enables precise epigenetic gene regulation. This in-depth analysis explores RG108’s mechanism, its unique non-covalent action, and strategic assay considerations for advanced cancer and stem cell research.

• Apicidin Disrupts Oocyte Maturation via HDAC Inhibition Mech

  2026-05-14

  This study demonstrates that Apicidin, a potent histone deacetylase inhibitor, impairs oocyte quality by disrupting spindle assembly and altering histone acetylation, leading to compromised meiotic progression and increased DNA damage. The findings deepen our understanding of Apicidin's reproductive toxicity and provide mechanistic insight relevant to both toxicology and epigenetic research.

• AZD3463: Advancing Translational Neuroblastoma Research

  2026-05-14

  This thought-leadership article explores the mechanistic depth and translational strategy behind AZD-3463, a dual ALK/IGF1R inhibitor, focusing on its application in neuroblastoma research. By integrating recent discoveries on pathway cross talk and resistance, the article offers actionable guidance for researchers seeking to harness AZD-3463 in complex oncology assays, and positions APExBIO’s reagent as a catalyst for next-generation translational breakthroughs.

• PD98059: Selective MEK Inhibitor for MAPK/ERK Pathway Studie

  2026-05-13

  PD98059 is a selective and reversible MEK inhibitor that blocks ERK1/2 phosphorylation, making it indispensable in cancer and neuroprotection research. Its precise modulation of the MAPK/ERK pathway enables controlled studies of cell proliferation, apoptosis, and ischemic injury mechanisms.

• YBX1, SHANK3 Methylation, and Cortical Interneuron Dysfuncti

  2026-05-13

  This study elucidates a mechanism where YBX1 regulates SHANK3 expression via DNA methylation in cortical interneurons and peripheral blood mononuclear cells in schizophrenia. These findings highlight cell-type-specific epigenetic dysregulation and propose SHANK3 promoter hypermethylation as a promising peripheral biomarker for early-stage schizophrenia.

• A 83-01: ALK-5 Inhibitor for Advanced TGF-β Pathway Studies

  2026-05-12

  A 83-01 (ALK inhibitor) empowers precision TGF-β/Smad pathway interrogation, enabling reproducible suppression of fibrotic signaling in high-content cell and organoid assays. This article details actionable workflows, troubleshooting strategies, and critical insights from landmark fibrosis research to maximize utility in EMT, cancer, and stem cell applications.

15937 records 1/1063 page Next 12345 下5页 Last page